METHODS: All clinical studies cited in support of the 2021 SSC adult guideline recommendations were identified. Original clinical studies were included, while editorials, reviews, non-clinical studies, and meta-analyses were excluded. For eligible studies, we recorded the proportion of male patients, percentage of each represented racial/ethnic subgroup (when available), and countries in which they were conducted. We also recorded the sex and location of the first and last authors. The World Bank classification was used to categorize countries.
RESULTS: The SSC guidelines included six sections, with 85 recommendations based on 351 clinical studies. The proportion of male patients ranged from 47 to 62%. Most studies did not report the racial/ ethnic distribution of the included patients; when they did so, most were White patients (68-77%). Most studies were conducted in high-income countries (77-99%), which included Europe/Central Asia (33-66%) and North America (36-55%). Moreover, most first/last authors were males (55-93%) and from high-income countries (77-99%).
CONCLUSIONS: To enhance the generalizability of the SCC guidelines, stakeholders should define strategies to enhance the diversity and representation in clinical studies. Though there was reasonable representation in sex among patients included in clinical studies, the evidence did not reflect diversity in the race/ethnicity and geographical locations. There was also lack of diversity among the first and last authors contributing to the evidence.
方法:确定了支持2021年SSC成人指南建议的所有临床研究。包括原始临床研究,而社论,reviews,非临床研究,荟萃分析被排除。对于符合条件的研究,我们记录了男性患者的比例,每个代表种族/族裔分组的百分比(如有),以及进行这些活动的国家。我们还记录了第一位和最后一位作者的性别和位置。世界银行的分类用于对国家进行分类。
结果:SSC指南包括六个部分,基于351项临床研究的85项建议。男性患者的比例为47%至62%。大多数研究没有报告纳入患者的种族/民族分布;当他们这样做时,大多数是白人患者(68-77%)。大多数研究是在高收入国家进行的(77-99%),其中包括欧洲/中亚(33-66%)和北美(36-55%)。此外,大多数第一/最后作者是男性(55-93%)和来自高收入国家(77-99%)。
结论:为了提高SCC指南的普遍性,利益相关者应制定策略,以增强临床研究的多样性和代表性。尽管临床研究中纳入的患者在性别方面有合理的代表性,证据没有反映种族/民族和地理位置的多样性.为证据做出贡献的第一作者和最后作者之间也缺乏多样性。